{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-311357","form_type":"8-K","ticker":"LBRX","cik":"0001691082","company_name":"LB PHARMACEUTICALS INC","filed_at":"2026-07-22T12:14:47+00:00","discovered_at":"2026-07-22T12:20:06.449446+00:00","generated_at":"2026-07-22T12:20:11.443178+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"LB Pharma accelerates Phase 3 NOVA-2 topline to H1 2027; cash runway into Q2 2029","bullets":["Topline results from Phase 3 NOVA-2 trial of LB-102 in schizophrenia now expected in first half of 2027, ahead of prior guidance.","Pre-NDA meeting with FDA scheduled for second half of 2027.","Cash runway expected to fund operations into Q2 2029 through multiple clinical readouts.","Phase 2 ILLUMINATE-1 trial in bipolar depression topline expected in Q1 2028.","Phase 2 trial of LB-102 in adjunctive MDD topline expected in first half of 2029."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-311357","json":"https://secwatch.observer/filing/0001193125-26-311357.json","markdown":"https://secwatch.observer/filing/0001193125-26-311357.md","text":"https://secwatch.observer/filing/0001193125-26-311357.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1691082/000119312526311357/0001193125-26-311357-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1691082/000119312526311357/d173035d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-22T12:20:11.443178+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}